Great Point Partners LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Great Point Partners LLC reported 39 stock positions worth $408.3 million. Its top holding was Apogee Therapeutics (APGE) at 7.7% of the portfolio, followed by Vor Biopharma (VOR, 7.6%) and Zura Bio (ZURA, 6.1%). Compared with Q4 2025, it opened 18 new positions, sold out of 8, added to 8 and reduced 4. The biggest buy was a new position in Sol-Gel Technologies (SLGL) and the biggest sale an exit from Disc Medicine (IRON).

Most Recent 13F
Q2 2026
Location
Greenwich, CT
CIK
0001281446
Portfolio Value
$408.3M (Q1 2026)
SEC Filing
0001172661-26-002272 ↗ filed May 15, 2026

Holdings Value

0$200.0M$400.0M$600.0M$800.0M Q1 2024: $641.6M Q1 2024 Q2 2024: $522.0M Q2 2024 Q3 2024: $331.4M Q3 2024 Q4 2024: $212.2M Q4 2024 Q1 2025: $184.0M Q1 2025 Q2 2025: $153.8M Q2 2025 Q3 2025: $239.5M Q3 2025 Q4 2025: $308.4M Q4 2025 Q1 2026: $408.3M $408.3M Q1 2026 Q2 2026: $424.4M Q2 2026

Holdings 39 stocks · $408.3M
APGE Apogee Therapeutics Inc. 7.71% 374,000 $31.5M No change
VOR Vor Biopharma Inc. 7.65% 1,750,000 $31.2M Add +27.7%
ZURA Zura Bio Ltd. 6.14% 4,215,930 $25.1M Add +10.5%
AMLX Amylyx Pharmaceuticals Inc. 5.96% 1,750,000 $24.3M No change
NKTR Nektar Therapeutics 5.58% 316,453 $22.8M Add +50.2%
SLGL Sol-Gel Technologies Ltd. 5.32% 274,363 $21.7M New
ALMS Alumis Inc. 4.62% 856,061 $18.9M New
DRUG Bright Minds Biosciences Inc. 3.93% 220,000 $16.1M New
ANNX Annexon Inc. 3.39% 2,500,000 $13.8M New
KALV Kalvista Pharmaceuticals Inc. 3.33% 675,000 $13.6M Reduce -1.6%
IMVT Immunovant Inc. 3.32% 545,625 $13.6M Reduce -27.3%
JBIO Jade Biosciences Inc. 3.32% 964,462 $13.6M Add +19.6%
CTNM Contineum Therapeutics Inc. Class A 2.56% 800,198 $10.5M Add +0.0%
ZBIO Zenas Biopharma Inc. 2.51% 524,066 $10.2M New
NGNE Neurogene Inc. 2.47% 500,000 $10.1M Add +42.9%
MLTX Moonlake Immunotherapeutics 2.28% 500,000 $9.3M New
CLYM Climb Bio Inc. 2.24% 1,334,130 $9.1M Add +36.2%
ORKA Oruka Therapeutics Inc. 2.20% 183,330 $9.0M No change
EPRX Eupraxia Pharmaceuticals Inc. 2.13% 1,200,000 $8.7M No change
VERA Vera Therapeutics Inc. 1.96% 199,348 $8.0M New
EVMN Evommune Inc. 1.83% 325,000 $7.5M No change
LBRX LB Pharmaceuticals Inc. 1.81% 300,000 $7.4M New
CMPX Compass Therapeutics Inc. 1.75% 1,350,000 $7.1M New
SCYX Scynexis Inc. 1.70% 7,554,347 $6.9M New
PALI Palisade Bio Inc. 1.46% 3,405,757 $6.0M New
CNTX Context Therapeutics Inc. 1.44% 2,238,496 $5.9M Reduce -52.2%
RLMD Relmada Therapeutics Inc. 1.44% 842,106 $5.9M New
SLN Silence Therapeutics PLC-ADR 1.32% 1,020,489 $5.4M Add +26.3%
UNCY Unicycive Therapeutics Inc. 1.28% 796,558 $5.2M No change
TENX Tenax Therapeutics Inc. 1.28% 327,307 $5.2M New
PMN Promis Neurosciences Inc. 1.16% 371,402 $4.7M New
CGEM Cullinan Therapeutics Inc. 1.04% 300,000 $4.3M Reduce -52.7%
IMMX Immix Biopharma Inc. 0.78% 350,000 $3.2M New
RZLT Rezolute Inc. 0.71% 951,809 $2.9M No change
PHVS Pharvaris NV 0.57% 82,800 $2.3M No change
HUMA Humacyte Inc. 0.56% 3,750,000 $2.3M New
AVTX Avalo Therapeutics Inc. 0.46% 124,666 $1.9M No change
ALKS Alkermes PLC 0.43% 50,000 $1.8M New
IRD Opus Genetics Inc. 0.36% 324,340 $1.5M New

Options reported separately and not counted above: IBRX puts ($23.0M), GALT calls ($2.2M), AVXL calls ($1.6M).

Portfolio Sells Q4 2025 → Q1 2026
IRON Disc Medicine Inc. Sold out 0.00% −6.44
RAPT Rapt Therapeutics Inc. Sold out 0.00% −6.38
SLNO Soleno Therapeutics Inc. Sold out 0.00% −6.00
DNTH Dianthus Therapeutics Inc. Sold out 0.00% −4.68
FULC Fulcrum Therapeutics Inc. Sold out 0.00% −2.93
IMVT Immunovant Inc. Reduce -27.3% 3.32% −2.86
UPB Upstream Bio Inc. Sold out 0.00% −2.64
RARE Ultragenyx Pharmaceutical Inc. Sold out 0.00% −2.24
CGEM Cullinan Therapeutics Inc. Reduce -52.7% 1.04% −1.08
SANA Sana Biotechnology Inc. Sold out 0.00% −0.92
CNTX Context Therapeutics Inc. Reduce -52.2% 1.44% −0.80
KALV Kalvista Pharmaceuticals Inc. Reduce -1.6% 3.33% −0.26

Portfolio Buys Q4 2025 → Q1 2026
SLGL Sol-Gel Technologies Ltd. New 5.32% +5.32
ALMS Alumis Inc. New 4.62% +4.62
DRUG Bright Minds Biosciences Inc. New 3.93% +3.93
ANNX Annexon Inc. New 3.39% +3.39
NKTR Nektar Therapeutics Add +50.2% 5.58% +2.69
ZBIO Zenas Biopharma Inc. New 2.51% +2.51
MLTX Moonlake Immunotherapeutics New 2.28% +2.28
VERA Vera Therapeutics Inc. New 1.96% +1.96
VOR Vor Biopharma Inc. Add +27.7% 7.65% +1.84
LBRX LB Pharmaceuticals Inc. New 1.81% +1.81
CMPX Compass Therapeutics Inc. New 1.75% +1.75
SCYX Scynexis Inc. New 1.70% +1.70
PALI Palisade Bio Inc. New 1.46% +1.46
RLMD Relmada Therapeutics Inc. New 1.44% +1.44
TENX Tenax Therapeutics Inc. New 1.28% +1.28
PMN Promis Neurosciences Inc. New 1.16% +1.16
CLYM Climb Bio Inc. Add +36.2% 2.24% +0.97
IMMX Immix Biopharma Inc. New 0.78% +0.78
HUMA Humacyte Inc. New 0.56% +0.56
ALKS Alkermes PLC New 0.43% +0.43
IRD Opus Genetics Inc. New 0.36% +0.36
NGNE Neurogene Inc. Add +42.9% 2.47% +0.13
SLN Silence Therapeutics PLC-ADR Add +26.3% 1.32% −0.28
ZURA Zura Bio Ltd. Add +10.5% 6.14% −0.34
CTNM Contineum Therapeutics Inc. Class A Add +0.0% 2.56% −0.41
JBIO Jade Biosciences Inc. Add +19.6% 3.32% −0.71

Options Activity Q4 2025 → Q1 2026
IBRX Immunitybio Inc. put New 3,000,800 $23.0M
GALT Galectin Therapeutics Inc. call New 800,000 $2.2M
AVXL Anavex Life Sciences Corp. call New 521,300 $1.6M

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 37$424.4MVOR, ABVX, VERA, ZURA, ALMS
Q1 2026 39$408.3MAPGE, VOR, ZURA, AMLX, NKTR
Q4 2025 29$308.4MAPGE, AMLX, ZURA, IRON, RAPT
Q3 2025 28$239.5MAMLX, RZLT, NKTR, ZURA, SLNO
Q2 2025 26$153.8MIONS, RZLT, AMLX, LEGN, ABVX
Q1 2025 31$184.0MCYTK, KALV, EOLS, ABVX, VRDN
Q4 2024 26$212.2MIONS, CYTK, KALV, VRDN, PLRX
Q3 2024 29$331.4MNGNE, ABVX, PLRX, EOLS, VRDN
Q2 2024 33$522.0MURGN, NGNE, ABVX, MRUS, PLRX
Q1 2024 35$641.6MNGNE, ALPN, URGN, ABVX, EOLS